Medicenna Therapeutics Corp. MDNAF
Annual
Quarterly
No annual revenue total was found in Medicenna Therapeutics Corp.'s SEC filings.
Medicenna Therapeutics Corp. (MDNAF) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
69.64M
+25.1% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MDNAF (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Toronto
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1807983
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | May 13, 2024 | May 13, 2024 |
| 6-K | Current report (foreign issuer) | Apr 30, 2024 | Apr 30, 2024 |
| 6-K | Current report (foreign issuer) | Apr 26, 2024 | Apr 26, 2024 |
| 6-K | Current report (foreign issuer) | Apr 25, 2024 | Apr 24, 2024 |
| 6-K | Current report (foreign issuer) | Apr 10, 2024 | Apr 9, 2024 |
| 6-K | Current report (foreign issuer) | Apr 9, 2024 | Apr 9, 2024 |
All 178 Medicenna Therapeutics Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.